These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31663869)

  • 1. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
    Ruley M; Belcher M; Sayre H; Coustasse A
    Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges for Managed Care from 340B Contract Pharmacies.
    Fein AJ
    J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
    Clark BL; Hou J; Chou CH; Huang ES; Conti R
    Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
    Lee CH; Chang J; McCombs J
    J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of 340B contract pharmacy growth with county-level characteristics.
    Nikpay S; Gracia G; Geressu H; Conti R
    Am J Manag Care; 2022 Mar; 28(3):133-136. PubMed ID: 35404549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
    Conti RM; Bach PB
    Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the Benefits of the 340b Drug Discount Program.
    Gerlach J; McSweeney S; Swearingen A; Coustasse A
    Health Care Manag (Frederick); 2018; 37(3):225-231. PubMed ID: 29901471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
    Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
    Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using 340B drug discounts to provide a financially sustainable medication discharge service.
    Wu T; Williams C; Vranek K; Mattingly TJ
    Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
    Health Resources and Services Administration, Department of Health and Human Services (HHS)
    Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 340B Drug Pricing Program and hospital provision of uncompensated care.
    Desai SM; McWilliams JM
    Am J Manag Care; 2021 Oct; 27(10):432-437. PubMed ID: 34668672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 340B Contract pharmacy growth by pharmacy ownership: 2009-2022.
    McGlave C; Bruno JP; Watts E; Nikpay S
    Health Aff Sch; 2024 Jan; 2(1):qxad075. PubMed ID: 38756399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
    Kantarjian HM; Chapman R
    J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notice regarding section 602 of the Veterans Health Care Act of 1992 inclusion of outpatient hospital facilities--PHS. Notice.
    Fed Regist; 1994 Jun; 59(107):29300-1. PubMed ID: 10135125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.